Tolmar Sync

A Simple & Powerful Inventory and Patient Management Solution for Your Practice

TOLMARsync® is Designed to Integrate with Your Practice Work Flow
TOLMARsync
Simple & Powerful
Order, Receive, Dispense, and Track ELIGARD

• Easy On-boarding and Training •

• Intuitive Reporting To Help Answer Key Business Questions •

• Broad Integration Capabilities Across Many Platforms •

• Integrated Benefit Verification Support •

• Easy On-boarding and Training

• Intuitive Reporting To Help Answer Key Business Questions

• Broad Integration Capabilities Across Many Platforms

• Integrated Benefit Verification Support

Easy Setup & Activation

TOLMARsync® features a 2D bar code scanner for streamlined installation and activation. Simply plug the Scanner into the USB port on your PC. The TOLMARsync scanner is already configured to read the ELIGARD 2D bar codes so you are ready to scan products.

TOLMARsync Scanner
Intuitive Easy-to-Use Interface
Allows you to work efficiently so you can spend more time with your patients.

 

Tolmar Sync User Interface

 

Powerful Reporting Options for Every Role in Your Practice
Doctor at work station
  • Robust reporting helps optimize inventory/ordering, track patients to minimize missed injections, and reconcile inventory.
     
  • Link multiple clinics together to keep track of large systems.
     
  • Track contract commitments across your entire organization.
     
  • Specific Navigation Reporting
     
    • Information tailored to the needs of Patient Navigators
       
    • Easy access to track, contact, and verify benefits of ELIGARD Patients
       
Tolmar Sync Report Preview

 

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

INDICATION

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

Please see full Prescribing Information for ELIGARD.

References

  1. Sartor O. Eur Urol. 2006
  2. ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.
  3. Prettyman J. Urologic Nursing 2019